Literature DB >> 2172404

Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection.

R L Ward1, D S Sander, G M Schiff, D I Bernstein.   

Abstract

In an evaluation of WC3 bovine rotavirus (serotype 6) vaccine in infants, some subjects experienced a natural serotype 1 rotavirus infection before vaccination and others after. Therefore, the effects of both WC3 and natural rotavirus strains as either primary or boosting immunogens on serotype-specific neutralizing antibody responses could be determined. After primary natural infection (symptomatic or asymptomatic), neutralizing antibody titers were highest to serotype 1 but were consistently high to serotype 3, and low titers (greater than or equal to 20) to serotypes 2 and 4 were often detected. Previous vaccination with WC3 had little effect on the magnitude of these responses. In contrast, subjects infected with serotype 1 strains before vaccination experienced large (average, 12-fold) rises in neutralizing antibody to human serotypes 1-4 when vaccinated with WC3. Thus, although WC3 and the natural strains are distinct serotypes, their epitopes were sufficiently similar that reinfection with WC3 could boost neutralizing antibody titers to human serotypes in subjects primed by a previous natural infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172404     DOI: 10.1093/infdis/162.6.1298

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Attenuation of a human rotavirus vaccine candidate did not correlate with mutations in the NSP4 protein gene.

Authors:  R L Ward; B B Mason; D I Bernstein; D S Sander; V E Smith; G A Zandle; R S Rappaport
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

3.  High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain.

Authors:  Nilah Monnier; Kyoko Higo-Moriguchi; Zhen-Yu J Sun; B V Venkataram Prasad; Koki Taniguchi; Philip R Dormitzer
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

Authors:  K Y Green; A Z Kapikian
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.

Authors:  Yuxiao Wang; Jingxin Li; Pei Liu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

6.  Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children.

Authors:  R L Ward; M M McNeal; D S Sander; H B Greenberg; D I Bernstein
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

7.  Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers.

Authors:  Pratibha G Ray; Shobhana D Kelkar
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

8.  Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.

Authors:  Romina Libster; Monica McNeal; Emmanuel B Walter; Andi L Shane; Patricia Winokur; Gretchen Cress; Andrea A Berry; Karen L Kotloff; Kwabena Sarpong; Christine B Turley; Christopher J Harrison; Barbara A Pahud; Jyothi Marbin; John Dunn; Jill El-Khorazaty; Jill Barrett; Kathryn M Edwards
Journal:  Pediatrics       Date:  2016-01-28       Impact factor: 7.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.